A few 2025 trials pointed in the same direction: toward treatments built to modify disease biology and better ways to measure ...

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.

The Kennedy College of Sciences, Department of Biological Sciences, invites you to attend a Ph.D. Proposal Defense in Applied Biology by Brandon Reder entitled "Morphological and physiological ...